Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.

The Lancet. Infectious diseases - 1 Sept 2012

Pearlman Brian L

Abstract excerpt

For the past decade, the standard treatment for chronic hepatitis C infection has been pegylated-interferon plus ribavirin. With US Food and Drug Administration approval of boceprevir and telaprevir--two protease inhibitors--the standard-of-care treatment for genotype-1 infection, the main genotype worldwide, is now peginterferon plus ribavirin and a protease inhibitor. Rates of sustained virological response or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Proline

Share to Protease Inhibitors

Share to Ribavirin

Source

Identifiers

PMID: 22647717
DOI: 10.1016/S1473-3099(12)70060-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.PMID 22647717Read ↗

Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials.Semantic proximity Read ↗

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.Semantic proximity Read ↗

Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.Semantic proximity Read ↗

Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.Semantic proximity Read ↗

Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.Semantic proximity Read ↗

Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].Semantic proximity Read ↗

Advances in the management of hepatitis C.Semantic proximity Read ↗

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.Semantic proximity Read ↗

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.Semantic proximity Read ↗

Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.